The value of CA19-9 dynamics in decision making for treatment of locally advanced pancreatic cancer.
作者信息
Rompen Ingmar F, Habib Joseph R, Sereni Elisabetta, Javed Ammar A
机构信息
Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY, USA.
出版信息
Gland Surg. 2024 Mar 27;13(3):458-460. doi: 10.21037/gs-23-477. Epub 2024 Mar 21.
Abstract
摘要
相似文献
1
The value of CA19-9 dynamics in decision making for treatment of locally advanced pancreatic cancer.CA19-9动态变化在局部晚期胰腺癌治疗决策中的价值
Gland Surg. 2024 Mar 27;13(3):458-460. doi: 10.21037/gs-23-477. Epub 2024 Mar 21.
2
Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.肿瘤相关抗原 19-9 水平变化作为局部晚期胰腺癌同步放化疗后总生存的预后标志物。
Int J Clin Oncol. 2017 Dec;22(6):1069-1075. doi: 10.1007/s10147-017-1129-7. Epub 2017 May 5.
3
Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.在接受剂量递增调强放疗和同期全剂量吉西他滨治疗的不可切除局部晚期胰腺癌中，碳水化合物抗原 19-9 的预后意义：一项前瞻性 1/2 期剂量递增研究的分析。
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):96-101. doi: 10.1016/j.ijrobp.2012.11.020. Epub 2012 Dec 19.
4
Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.CA19-9反应在预测局部晚期胰腺癌诱导化疗后可切除性方面的附加价值。
HPB (Oxford). 2018 Jul;20(7):605-611. doi: 10.1016/j.hpb.2018.01.001. Epub 2018 Feb 21.
5
Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer.对于不可切除的局部晚期胰腺癌，CA19-9水平降低的持续时间比其降低速率是更好的预后因素。
Cancers (Basel). 2021 Aug 22;13(16):4224. doi: 10.3390/cancers13164224.
6
Combined CT and serum CA19-9 for stratifying risk for progression in patients with locally advanced pancreatic cancer receiving intraoperative radiotherapy.联合CT与血清CA19-9对接受术中放疗的局部晚期胰腺癌患者的疾病进展风险进行分层。
Front Oncol. 2023 Apr 14;13:1155555. doi: 10.3389/fonc.2023.1155555. eCollection 2023.
7
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.改良 FOLFIRINOX 方案新辅助治疗与中国局部晚期胰腺癌患者结局的相关性。
Oncologist. 2019 Mar;24(3):301-e93. doi: 10.1634/theoncologist.2018-0696. Epub 2018 Nov 20.
8
Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.中性粒细胞与淋巴细胞比值及糖类抗原19-9作为晚期胰腺癌一线化疗患者的预后标志物
World J Gastrointest Oncol. 2021 Aug 15;13(8):915-928. doi: 10.4251/wjgo.v13.i8.915.
9
The value of dynamic contrast enhanced ultrasound (DCE-US) in monitoring treatment effect of high-intensity focused ultrasound (HIFU) in locally advanced pancreatic cancer (LAPC).动态对比增强超声（DCE-US）在监测局部进展期胰腺癌（LAPC）高强度聚焦超声（HIFU）治疗效果中的价值。
Clin Hemorheol Microcirc. 2021;77(3):323-333. doi: 10.3233/CH-201020.
10
The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.CA19-9 检测在胰腺癌不可逆电穿孔治疗后的价值。
Anticancer Res. 2019 Nov;39(11):6193-6196. doi: 10.21873/anticanres.13827.
本文引用的文献
1
Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment.胰腺癌局部复发的进展及其对治疗的影响。
Ann Surg. 2024 Aug 1;280(2):317-324. doi: 10.1097/SLA.0000000000006142. Epub 2023 Oct 23.
2
Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study.局部晚期胰腺癌患者两个月诱导化疗后 CA19-9 的最低和最佳反应：一项全国多中心研究。
Ann Surg. 2024 May 1;279(5):832-841. doi: 10.1097/SLA.0000000000006021. Epub 2023 Jul 21.
3
"Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022.局部进展期胰腺癌的“转化治疗”：国际胰腺病学会（IAP）与日本胰腺学会（JPS）2022 年联合会议研究组立场文件。
Pancreatology. 2023 Sep;23(6):712-720. doi: 10.1016/j.pan.2023.06.005. Epub 2023 Jun 7.
4
Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.新辅助化疗治疗胰腺癌：质量优于数量。
J Surg Oncol. 2023 Jul;128(1):41-50. doi: 10.1002/jso.27265. Epub 2023 Apr 11.
5
Neoadjuvant therapy for pancreatic cancer.胰腺癌的新辅助治疗。
Nat Rev Clin Oncol. 2023 May;20(5):318-337. doi: 10.1038/s41571-023-00746-1. Epub 2023 Mar 17.
6
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
7
Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.局部胰腺癌新辅助治疗后的手术切除率：荟萃分析
Br J Surg. 2022 Dec 13;110(1):34-42. doi: 10.1093/bjs/znac354.
8
A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal Adenocarcinoma.在胰腺导管腺癌切除术后，只有在有过渡性循环肿瘤细胞的患者中，辅助治疗的延迟才与更差的预后相关。
Ann Surg. 2023 Jun 1;277(6):866-872. doi: 10.1097/SLA.0000000000005710. Epub 2022 Sep 15.
9
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).多药诱导化疗治疗局部晚期胰腺癌中 CA19-9 的预后和预测价值：一项前瞻性、多中心 II 期试验（NEOLAP-AIO-PAK-0113）的结果。
ESMO Open. 2022 Aug;7(4):100552. doi: 10.1016/j.esmoop.2022.100552. Epub 2022 Aug 12.
10
Conduits in Vascular Pancreatic Surgery: Analysis of Clinical Outcomes, Operative Techniques, and Graft Performance.血管胰腺手术中的导管：临床结果、手术技术和移植物性能分析。
Ann Surg. 2023 Jul 1;278(1):e94-e104. doi: 10.1097/SLA.0000000000005575. Epub 2022 Jul 15.
Zotero 插件